, Volume 8, Issue 1, pp 60-70
Date: 09 Dec 2012

CARs in Chronic Lymphocytic Leukemia – Ready to Drive

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access


Adoptive transfer of antigen-specific T cells has been adapted by investigators for treatment of chronic lymphocytic leukemia (CLL). To overcome issues of immune tolerance which limits the endogenous adaptive immune response to tumor-associated antigens (TAAs), robust systems for the genetic modification and characterization of T cells expressing chimeric antigen receptors (CARs) to redirect specificity have been produced. Refinements with regards to persistence and trafficking of the genetically modified T cells are underway to help improve potency. Clinical trials utilizing this technology demonstrate feasibility, and increasingly, these early-phase trials are demonstrating impressive anti-tumor effects, particularly for CLL patients, paving the way for multi-center trials to establish the efficacy of CAR+ T cell therapy.

Chitra Hosing and Partow Kebriaei contributed equally to this work